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Abstract
Background: Human luteinizing hormone (LH) and chorionic gonadotropin (hCG) are glycoprotein hormones
regulating development and reproductive functions by acting on the same receptor (LHCGR). We compared the LH
and hCG activity in gonadal cells from male mouse in vitro, i.e. primary Leydig cells, which is a common tool used
for gonadotropin bioassay. Murine Leydig cells are naturally expressing the murine LH receptor (mLhr), which binds
human LH/hCG.
Methods: Cultured Leydig cells were treated by increasing doses of recombinant LH and hCG, and cell signaling,
gene expression and steroid synthesis were evaluated.
Results: We found that hCG is about 10-fold more potent than LH in cAMP recruitment, and slightly but significantly
more potent on cAMP-dependent Erk1/2 phosphorylation. However, no significant differences occur between LH and
hCG treatments, measured as activation of downstream signals, such as Creb phosphorylation, Stard1 gene expression
and testosterone synthesis.
Conclusions: These data demonstrate that the responses to human LH/hCG are only quantitatively and not
qualitatively different in murine cells, at least in terms of cAMP and Erk1/2 activation, and equal in activating
downstream steroidogenic events. This is at odds with what we previously described in human primary granulosa cells,
where LHCGR mediates a different pattern of signaling cascades, depending on the natural ligand. This finding is
relevant for gonadotropin quantification used in the official pharmacopoeia, which are based on murine, in vivo
bioassay and rely on the evaluation of long-term, testosterone-dependent effects mediated by rodent receptor.
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Background
Human luteinizing hormone (LH) and chorionic gonado-
tropin (hCG) are glycoprotein hormones which bind the
same receptor (LHCGR), belonging to the superfamily of
the G protein-coupled receptors (GPCRs) (Ascoli et al.,
2002). Although they share similar molecular structures,
the two hormones have distinct physiological roles [1]. LH
is produced by the pituitary in a pulsatile fashion, inducing
ovulation and maintenance of the corpus luteum in
females. In adult males, LH regulates spermatogenesis
acting on Leydig cells located in the testes, by controlling
testosterone production [2, 3]. hCG is the primate-specific
pregnancy hormone produced by trophoblast cells [4].
During development, maternal hCG stimulates the prolif-
eration of the male foetus’ Leydig cells. Barely detectable
amounts of pituitary hCG produced during the fertile age
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of both males and females were also demonstrated in
circulation [5], but its role is still unknown.
In vivo bioassays: methods for human gonadotropin
quantification mediated by rodent Leydig cells
Due to the hCG action on LHCGR and the long half-
life, this hormone is used instead of LH for treatment of
infertility in males and for assisted reproduction in
females. Pharmacological preparations are quantified by
in vivo bioassays, which aim to assess the effects (e.g.
organ weight) of hormones injected in a living rat or
mouse [6] to evaluate gonadotropin bioactivity, thus
inferring their dosage for clinical purposes [7]. Indeed,
official Pharmacopoeias recognize the biological activity
of LH and hCG preparations as determined by the
so-called “Van Hell bioassay” [8]. Briefly, a fixed dose
of gonadotropin is administered by daily subcutaneous
injection in groups of ten 21–28 days old immature
male rats. The animals are killed five days after the
first injection and the seminal vesicles dissected out,
dried and weighted to evaluate seminal vesicle weight
gain (SVW). LH and hCG are calibrated against an
International Standard using the Van Hell bioassay,
which does not discriminate between LH and hCG
bioactivity [9].
Main testicular functions, e.g. spermatogenesis, are
critically depending on testosterone in mice and rats [2].
The steroid hormone is produced by Leydig cells
expressing the murine LH receptor (mLhr), upon LH
stimulation. Therefore, SVW evaluated by rat/mouse
bioassays may be the representation of the gonadotro-
pins’ steroidogenic potential triggered by heterologous
receptors, not providing the full spectrum of LH- and
hCG-specific, non-steroidogenic functions exerted by
these molecules in the reproductive endocrine milieu of
women.
LH and hCG intracellular signaling
By acting on the common receptor, LH and hCG acti-
vate several signaling cascades typically associated to
rhodopsin-like GPCRs in the human as well as other mam-
mals [10]. Hormone binding to LHCGR triggers the activa-
tion of adenylyl cyclase through Gαs protein, resulting in
intracellular cyclic adenosine-monophosphate (cAMP)
increase, in downstream activation of the protein kinase A
(PKA) [11, 12] which, in turn, induces extracellular signal-
regulated kinases 1 and 2 (ERK1/2) phosphorylation
[13]. PKA also mediates the activation of the cAMP-
response element-binding protein (CREB), modulating
the expression of target genes, such as the steroidogenic
acute regulatory protein (STARD1) gene, and testosterone
production. Previous studies demonstrated different inter-
actions between the gonadotropins and their common re-
ceptor [14–17], as well as specific intracellular signaling
and downstream events in goat and human granulosa
lutein cells in vitro [18–20]. Especially, hCG has higher
cAMP-mediated steroidogenic and pro-apoptotic poten-
tial than LH, which, in turn is more effective in activating
anti-apoptotic and proliferative events via ERK1/2 and
AKT-pathways in vitro, while similar kinetics of intracellu-
lar cAMP reversibility were found in mouse Leydig tumor
cells (MLTC-1) stimulated by the two human gonadotro-
pins [21]. However, an in-depth comparison between the
human LH- and hCG-mediated signaling in Leydig cells is
still lacking.
Aim of the study
The aim of this study is to compare the signal transduc-
tion pathways elicited by human LH and hCG in mouse
Leydig cells, which are commonly used to quantify
human gonadotropins for clinical purposes, using an in
vitro approach. Especially, cAMP production, ERK1/2
and CREB phosphorylation (pERK1/2 and pCREB,
respectively), target gene expression and testosterone
synthesis were evaluated. Mouse cells are naturally
expressing the murine LH receptor, which shares high,
but not complete sequence identity with LHCGR, as well
as binding capability to human LH and hCG [13, 22].
However, it should be taken into account that some dis-
crepancy may be observed between human and rodent
LH receptor-mediated signals, as previously observed in
the monkey Callithrix jacchus [23]. This study may pro-
vide new insights useful for interpreting the significance of
rat/mouse in vivo bioassays, i.e. the methods for unit
assignment to gonadotropins used for pharmacological
treatment in humans. Human LH receptor mediates both
quantitatively and qualitatively LH- and hCG-dependent
signals in human primary granulosa cells [18, 19], reveal-
ing that LHCGR discriminates hormone-specific events.
Therefore, we challenge the concept that gonadotropins’
activity can be properly characterized by the assessment of
testosterone-dependent endpoints.
Methods
Recombinant Gonadotropins
Human recombinant LH (Luveris) and hCG (Ovitrelle)
were kindly provided by Merck KGaA (Darmstadt,
Germany).
Leydig cells isolation and culture
Leydig cells were collected from 3–5 months-old
C57BL6 mice following a validated protocol [24], under
the permission of the local Animal Ethics Committee
and current animal protection laws. Briefly, testes were
mechanically dissociated and subjected to 20 mg/ml col-
lagenase (Sigma-Aldrich, St. Louis, MO, USA) treatment
by gentle shacking at 37 °C for 20 min. Cell suspension
was filtered by a 100 μm Nylon mesh and Leydig cells
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were isolated by 0–100% v/v Percoll linear density gradient
(GE Healthcare, Little Chalfont, UK) through centrifuga-
tion (800 x g; 45 min). Purity of the cell preparations was
verified by 3β-hydroxysteroid dehydrogenase (3βHSD)
assay [25]. Depending on the endpoint measured, Leydig
cells were seeded in multi-well plates, in pH = 7.4 minimal
essential medium (MEM) (Gibco, Thermo Fisher Scientific,
Waltham, MA, USA), supplemented with 0.07% serum
albumin (Sigma-Aldrich), 100 U/ml penicillin, 50 μg/ml
streptomycin and 25 mM Hepes (Gibco). Cells were main-
tained two days in an incubator at 37 °C and 5% CO2
before stimulation.
cAMP stimulation protocol and measurement
To evaluate cAMP accumulation upon LH or hCG
stimulation, a validated protocol was followed [26].
Briefly, Leydig cells were seeded in 24-well plates (5 x 104
cells/well) and cultured 2 days before stimulation. Cells
were treated with increasing doses of LH or hCG (1 pM-
100 nM range), in the presence of 500 μM of phosphodi-
esterases inhibitor 3-isobutyl-1-methylxanthine (IBMX)
(#I5879, Sigma-Aldrich) [27]. Cells stimulated by 1 μg/ml
cholera toxin (CTX) (Sigma-Aldrich) [28] were used as
positive control, while unstimulated cells served as nega-
tive control (basal condition). After 3 h of incubation,
samples were frozen. Total cAMP levels were evaluated
using the Cyclic AMP Direct EIA kit (Arbor Assays, Ann
Arbor, MI, USA), following the supplier’s instructions and
signals were measured by a Victor3 multilabel plate reader
(PerkinElmer Inc., Waltham, MA, USA). Data were en-
tered into a curve fitting software and represented using a
log regression analysis, as previously described [29].
Western blot analysis
pErk1/2 and pCreb levels induced by LH or hCG treat-
ment were analyzed by Western blotting, as previously
described [18, 19, 29, 30]. Briefly, Leydig cells were
seeded in 96-well plates (1 x 105 cells/well) and treated
15 min by increasing doses of LH or hCG (1 pM-100
nM range). 10 μM of the mitogen-activated protein
kinases (Mek) inhibitor U0126 (#U120, Sigma-Aldrich),
or 10 μM of the PKA inhibitor H-89 (#B1427, Sigma-
Aldrich) [31] were also used where appropriate. Cells
were immediately lysed for protein extraction in 4 °C-
cold RIPA buffer added with PhosStop phosphatase in-
hibitor cocktail and protease inhibitor cocktail (Roche,
Basel, Switzerland). pErk1/2 and pCreb activation were
evaluated by 12% SDS-PAGE and Western blotting,
using specific antibodies (#9101 and #9198, respectively;
Cell Signaling Technology Inc., Danvers, MA, USA).
Total Erk1/2 served as loading control (#4695; Cell
Signaling Technology Inc.). Signals were revealed by ECL
chemiluminescent compound (GE HealthCare), after in-
cubation of the membranes with a secondary anti-rabbit
horseradish peroxidase-conjugated antibody (#NA9340V;
GE HealthCare). Western blotting signals were acquired
by the QuantityOne analysis software (Bio-Rad Laborator-
ies Inc., Hercules, CA, USA) and semi-quantitatively eval-
uated by the ImageJ software (U. S. National Institutes of
Health, Bethesda, MD, USA) [32].
Stimulation for gene expression analysis and evaluation
by Real-time PCR
The hCG and LH 80% effective doses (EC80s) were
calculated from the aforementioned cAMP dose–re-
sponse curves, and were taken as the lowest, maximally
activating gonadotropin concentrations (100 pM hCG
and 1 nM LH), as previously described [19, 29]. EC80s
were used as fixed doses for the gene expression
analysis.
Leydig cells were seeded in 12-well plates (1 x 105
cells/well) and stimulated 12 h by LH and hCG. Samples
were lysed and subjected to RNA extraction using the
automated extractor EZ1 Advanced XL (Qiagen, Hilden,
Germany). Equal amounts of total RNA were retro-
transcribed by iScript reverse transcriptase (Bio-Rad
Laboratories Inc.) according to the following protocol:
25 °C for 5 min; 42 °C for 30 min; 85 °C for 5 min. Quanti-
tative real-time PCR was performed in triplicates using
specific mouse Stard1 gene primer sequences (fwd: 5′-
ACAGACTCTATGAAGAACTT-3′; rev: 5′-GACCTT-
GATCTCCTTGAC-3′) and settings: 95.0 °C for 30 s;
95.0 °C for 3 s - 45 cycles; 57.0 °C for 30 s. Normalized
gene over the mouse hypoxanthine phosphoribosyltrans-
ferase (Hprt) gene expression (fwd: 5′-TTGCTCGAGAT
GTCATGAAGGA-3′; rev: 5′-AGCAGGTCAGCAAAGAA
CTTATAG-3′) was evaluated using the 2-ΔΔCt method
[33]. Primer sequences were designed and validated as
previously described [18, 19, 29].
Testosterone stimulation protocol and measurement
Leydig cells were seeded in 12-well plates (1 x 105
cells/well) and treated by increasing doses of LH and
hCG (1 pM-100 nM range), in the presence of 500 μM
IBMX. U0126 or H-89 were used where appropriate. The
stimulations were blocked by immediate freezing of the
samples after 24 h, then total testosterone was measured
in the media by an immunoassay analyser (ARCHITECT
2nd Generation Testosterone system; Abbot Diagnostics,
Abbott Park, Chicago, IL, USA).
Alignment of LH receptor amino acid sequences
The amino acid sequences of mouse, rat (rLhr) and hu-
man LH receptor were aligned by UniProt on-line tool
(http://www.uniprot.org/align/) using default settings.
The percentage of sequence identity among LHCGR,
mLhr and rLhr were performed using the National
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Center for Biotechnology Information (NCBI) BLAST
tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Statistical analysis
cAMP and testosterone dose–response data were repre-
sented as total levels over basal, or normalized as
percentage of the maximal response. pErk1/2 and pCreb
semi-quantitative signals were normalized over total ERK
and expressed in relative units. Data from gene expression
analysis were represented as relative expression. All data
were plotted as means ± standard error of mean (SEM).
Mann-Whitney’s U-tests, two-way ANOVA followed by
Bonferroni post-test or non-linear regressions were
performed as appropriate. Differences were considered
significant for P < 0.05. Statistical analysis was performed
using the GraphPad Prism software (GraphPad Software
Inc., San Diego, CA, USA).
Results
Evaluation of cAMP production
The Leydig cells isolation protocol was validated by the
3βHSD assay [24, 25], resulting in more than 95% purity.
LH- and hCG-induced total cAMP productions were
compared in murine primary Leydig cells by dose–re-
sponse experiments, in the presence of IBMX, and evalu-
ated by ELISA (Fig. 1). Although cAMP absolute levels
suggest overall low response to human gonadotropin
(Additional file 1), the treatments resulted in hormone-
specific dose–response curves and significantly differ-
ent half maximal effective concentrations (EC50) (LH
EC50 = 192 ± 53.96 pM; hCG EC50 = 18.64 ± 10.14 pM;
means ± SEM; Mann-Whitney’s U-test; P = 0.0286; n = 4).
This reveals an approximately 10-fold higher potency of
hCG versus LH, in terms of cAMP production, in spite of
the similar cAMP plateau levels achieved upon 100 nM
LH or hCG treatment.
Analysis of ERK1/2 and CREB phosphorylation
The LH- and hCG-induced pCreb and pErk1/2 activa-
tions were compared by dose–response experiments in
15 min-stimulated primary murine Leydig cells. Cells
were treated by increasing LH or hCG doses, then pCreb
and pErk1/2 levels were evaluated by Western blotting
and semi-quantitatively measured (Fig. 2).
Treatment by gonadotropins induced pErk1/2 activation
in different concentration ranges, compared to untreated
cells (LH = 100 pM-100 nM; hCG = 10 pM-100 nM; two-
way Anova and Bonferroni post-test; P < 0.05; n = 5). The
comparison between LH- and hCG-mediated pErk1/2
activation was also performed. We found higher Erk1/2
phosphorylation levels upon hCG versus LH stimulation,
within the 100 pM-100 nM range (Two-way Anova and
Bonferroni post-test, P < 0.05; n = 5).
pCreb activation occurs upon both LH and hCG treat-
ment in the 10 pM-100 nM range compared to controls
(two-way Anova and Bonferroni post-test; P < 0.05; n = 5),
while no significant differences between LH- and hCG-
induced pCreb levels were found (two-way Anova and
Bonferroni post-test; P = 0.08; n = 5), not reflecting the
hormone-specific differences observed in total cAMP
production.
Gene expression
The expression of the steroidogenesis-related Stard1
gene was analyzed as a downstream effector of the
cAMP/PkA-pathway. Mouse Leydig cells were main-
tained 12 h in the presence of the LH or hCG EC80 (100
pM hCG; 1 nM LH), as the lowest dose maximally acti-
vating cAMP, and gene expression was evaluated by real
time PCR (Fig. 3). Stard1 gene expression increased
upon both LH and hCG treatments compared to basal
(LH = 1.29 ± 0.13 relative units; hCG = 1.19 ± 0.04 rela-
tive units; Basal = 1.0 ± 0.0 relative units; means ± SEM;
Mann-Whitney’s U-test; P < 0.05; n = 4). However, no
significant differences between LH- and hCG-induced
Stard1 expression were found (Mann-Whitney’s U-test;
P = 1.00; n = 4), reflecting its dependence on pCreb
activation.
Evaluation of steroid production
The effects of LH and hCG increasing doses (1 pM-100
nM range) on testosterone production was evaluated in
Fig. 1 Comparison between LH- and hCG-induced cAMP production
by dose–response experiment. Murine primary Leydig cells were
stimulated by increasing doses of hCG and LH, in the presence of
500 μM IBMX. Total cAMP was measured after 3 h of incubation and
cAMP levels were normalized as percentage of the maximal response.
All the results are represented as means ± SEM in a logarithmic X-axis,
then non-linear regressions were plotted. The EC50 cAMP values were
compared (LH EC50 = 192 ± 53.96 pM; hCG EC50 = 18.64 ± 10.14 pM;
means ± SEM; Mann-Whitney’s U-test; P = 0.0286; n = 4)
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murine primary Leydig cells. The steroid hormone was
measured by immunoassay in the media of 24 h-stimu-
lated cells. Since testosterone synthesis depends on
intracellular cAMP, 500 μM IBMX was added 20 min
before gonadotropins to optimize the steroid production
[34]. No significant differences between LH- and hCG-
induced testosterone production were found, resulting
in similar dose–response curves and EC50s (hCG EC50 =
36.66 ± 12.25 pM; LH EC50 = 50.08 ± 18.03 pM; means ±
SEM; Mann-Whitney’s U-test; P = 1.00; n = 5). Testoster-
one increased similarly by either LH or hCG in a dose-
dependent manner (Fig. 4), not reflecting the different
LH- and hCG-induced cAMP production. The reliability
of the hormone detection was confirmed performing
representative measurements of steroids, i.e. 17alpha-
OH-progesterone (Additional file 2), androstenedione
(Additional file 3) and testosterone (Additional file 4), by
liquid chromatography-mass spectrometry (LC-MS)
following a previously validated method [35]. Levels of
dehydroepiandrosterone (DHEA) were also measured
and they are undetectable.
pERK1/2 and pCREB activation in the presence of specific
inhibitors
The results obtained so far indicate that LH and hCG
treatments result in different responses measured as early
signalling events occurring upon receptor activation, i.e.
Fig. 2 Evaluation of pErk1/2 and pCreb activation upon LH and hCG
treatment. a Mouse Leydig cells were stimulated by increasing doses
of LH and hCG. The phosphorylation of Erk1/2 and Creb was evaluated
after 15 min by Western blotting (image representative of five
independent experiments). b, c Densitometric analysis of pErk1/2 (b)
and pCreb (c) signals. The values were normalized over total ERK and
represented as means ± SEM, then statistically evaluated (§ = significant
vs control; * = significant LH vs hCG; two-way ANOVA and Bonferroni
post-tests; P < 0.05; n = 5)
Fig. 3 Stard1 gene expression analysis. The expression of Stard1
gene was evaluated in 12 h EC80 LH- or hCG-stimulated mouse
primary Leydig cells by real-time PCR. Unstimulated cells served as
control. Each value was normalized over the Hprt gene expression
and graphically represented as fold increase over unstimulated
controls in relative units scale (means ± SEM). Gene expression levels
were compared (§ = significant vs control; Mann-Whitney’s U-test;
P < 0.05; n = 4)
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cAMP and pErk1/2 activation, but not in the downstream
Creb phosphorylation, Stard1 gene expression and
testosterone synthesis. Taken together, these data
suggest that both LH and hCG treatments result in
qualitatively similar activation of balancing mecha-
nisms orchestrated by pro- and anti-steroidogenic
signals at the intracellular level, possibly mediated
through cAMP and pErk1/2 [36–38], which results in
equal pCreb activation. Therefore, the contribution of
the cAMP/PkA- and Erk1/2-pathway in steroidogene-
sis was investigated by using specific inhibitors.
pErk1/2 and pCreb activation were analysed in mouse
Leydig cells stimulated by LH or hCG, in the presence
of specific Mek and PkA inhibitors, i.e. U0126 and H-89,
respectively. Cells were stimulated for 15 min with LH
or hCG EC80 doses, in the presence or in the absence of
U0126 or H89, and pErk1/2 and pCreb levels were
evaluated by Western blotting (Fig. 5). The treatment by
U0126 resulted in failure of LH/hCG-induced Creb and
Erk1/2 phosphorylation. Interestingly, PkA blockade by
H-89 resulted in tonic, LH/hCG-not sensitive pErk1/2
activation, as previously observed in COS-7 cells [29],
and complete abolition of Creb phosphorylation.
Steroid production in the presence of specific inhibitors
Selective inhibitors were used to induce Mek and PkA
blockade and testosterone production was measured in
24 h-stimulated cells by LH and hCG EC80s (Fig. 6).
Both treatments impaired the gonadotropin-induced tes-
tosterone synthesis, revealing that both the Erk1/2- and
PkA-pathways are required for gonadotropin-stimulated
steroidogenesis in Leydig cells. Interestingly, H-89
significantly decreased testosterone production even in
gonadotropin-untreated mouse Leydig cells, suggesting
that Pka is fundamental for the maintenance of steroid
synthesis at basal level.
Analysis of LH receptor sequences and intracellular
interactions
LHCGR and rodent LH receptor amino acid sequences
were compared by on-line analysis tools and are avail-
able as additional file (Additional file 5). The alignment
Fig. 4 Comparison between LH- and hCG-induced testosterone
production in murine primary Leydig cells. The steroid was measured
in 24 h-stimulated cells by increasing LH and hCG doses, in the
presence of 500 μM IBMX. a Total testosterone levels was measured by
immuno-assay and represented as means ± SEM in ng/ml, then non-
linear regressions were plotted. b Testosterone levels were normalized
in percentage of the maximal response. EC50 values were statistically
compared (hCG EC50 = 36.66 ± 12.25 pM; LH EC50 = 50.08 ± 18.03 pM;
means ± SEM; Mann-Whitney’s U-test; P = 1.00; n = 5)
Fig. 5 Analysis of LH/hCG-induced ERK and CREB phosphorylation in
the presence/absence of specific inhibitors. Murine primary Leydig
cells were stimulated 15 min by EC80 LH or hCG, in the presence or in
the absence of PKA and MEK inhibitors (H-89 and U0126, respectively).
pERK and pCREB levels were evaluated by Western blotting (image
representative of three independent experiments)
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of mLhr and rLhr revealed that the two molecules are
overall structurally similar (94.2% identity), reflecting
their evolutionary closeness [2, 10], while lower
sequence identity was observed by mouse/rat versus
human receptor comparison (mLhr versus LHCGR =
81.93%; rLhr versus LHCGR = 83.93%), especially at the
hinge region (Table 1).
Discussion
In the present study, we compared the LH- and hCG-
induced steroidogenic signaling, in mouse primary
Leydig cells in vitro. cAMP production, pErk1/2 and
pCreb activation, as well as gene expression and steroid
synthesis were evaluated, demonstrating that human LH
and hCG treatments result in quantitatively different,
early intracellular events (i.e. cAMP and PkA-dependent
pErk1/2 activation), in mouse Leydig cells. Especially,
hCG has higher steroidogenic potential than LH, due to
its stronger activity on cAMP/PkA-pathway activation.
However, hormone-specific effects are not maintained in
the downstream Stard1 gene expression levels and steroid
production in vitro, which occurs within the physiological
range in mice [39, 40]. Each endpoint was evaluated at the
proper time required to optimally measure its activation
by practical methods, based on previous studies demon-
strating their inter-dependency [18, 19, 29, 30].
Implications for gonadotropins quantification by in vivo
bioassays
This study provides new insights of relevance for the Van
Hell in vivo bioassay, which aims to infer gonadotropin
dosage for clinical purpose in humans [7] evaluating their
bioactivity in a living rat or mouse [6]. Our results
support that both human LH and hCG equally acts
on testosterone production in rodent Leydig cells in vitro,
not differentiating the ligand-dependent events that we
demonstrated earlier in human granulosa cells [18, 19].
These cells are naturally expressing the human LH and
hCG receptor, which mediates both quantitatively and
qualitatively different intracellular signaling and down-
stream events, depending on ligand. Especially, LH-
specific signals concern the predominant activation of
proliferative and anti-apoptotic ERK1/2- and AKT-
pathways, while treatment by hCG induced preferential
cAMP/PKA-mediated steroidogenesis [18, 19]. Therefore,
the in vivo bioassays might not fully appropriate for infer-
ring the full spectrum of gonadotropin bioactivity in the
human since they are based only on testosterone-
dependent endpoints, detecting only one aspect of com-
plex intracellular signaling patterns [41]. Reasonably, in
vivo bioassays do not differentiate between LH- and hCG-
specific activity and disregard, for instance, effects on pro-
liferation/apoptosis important for final follicle maturation
in the human ovary.
Different early signaling mediated by LH and hCG
cAMP is an early mediator of steroidogenic signals,
downstream the activation of gonadotropin receptors in
steroidogenic cells [11]. Consistent with previous reports
[18, 19], we found that hCG has an about 10-fold higher
potency than LH in cAMP recruitment, in spite of
similar plateau levels. This result corroborates what
previously described in human granulosa cells naturally
expressing the human receptor, where treatment by hCG
resulted in higher cAMP/PkA pathway activation than
LH in vitro, both in the presence and in the absence of
FSH [18–20], suggesting a different steroidogenic poten-
tial by the two molecules. Consistently with the cAMP/
PkA dependence, hCG treatment resulted in higher,
dose-dependent, early (15 min) pErk1/2 activation than
LH. This result mismatches what we previously obtained
in human granulosa cells in vitro [18], where LH treat-
ment resulted in higher pERK1/2 activation than hCG,
revealing a qualitatively different, cAMP-independent
signaling depending on the ligand. Taken together,
these data suggest that human granulosa cell system
Fig. 6 Evaluation of testosterone production upon LH or hCG
stimulation in the presence or absence of specific inhibitors, in
mouse Leydig cells. The cells were stimulated 24 h by EC80 LH and
hCG, in the presence or absence of H-89 or U0126. Total testosterone
levels were measured by immune-assay and represented as means ±
SEM (§ = significant vs “unstimulated, no inhibitors”; * = significant
LH/hCG vs corresponding LH/hCG samples without inhibitor; Mann-
Whitney’s U-test; P < 0.05; n = 4)
Table 1 Identity between human, mouse and rat LH receptors
LHCGR vs mLhr LHCGR vs rLhr mLhr vs rLhr
Total receptor 81.9% 83.9% 94.2%
Hinge region 80.0% 81.9% 95.0%
TMD + ICD 88.0% 90.0% 93.0%
Legend: TMD transmembrane domain, ICD intracellular domain
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discriminates between LH and hCG, while murine
Leydig cell does not. Unfortunately, the direct evi-
dence that Erk1/2 phosphorylation occurs through
PkA upon LH/hCG treatment in Leydig cells cannot
be demonstrated, due to the complete abolition of
gonadotropin-mediated signaling by the PKA inhibitor
H-89 (Fig. 5), which results in slight, tonic pErk1/2
activation.
Similarities between LH- and hCG-mediated signaling
downstream cAMP/Pka
Interestingly, we found no significant differences between
LH- and hCG-induced pCreb levels in mouse primary
Leydig cells, in spite a higher potency of hCG on upstream
cAMP production. Thus, the two human hormones
induced similar Lhr-mediated Creb phosphorylation, trig-
gering its same, maximal activation in a dose-dependent
manner. It is known that pERK1/2 activation supports
both steroidogenic signals and GPCR downregulation
[42], however, the levels of Erk1/2 and Creb phosphoryl-
ation induced by low LH/hCG doses (i.e. 101 and 102 pM)
are close to the detection limits, not allowing to reliably
address why gonadotropin treatments result in equal
pCreb activation in the entire dose-range. Anyway, this
does not correspond with that previously demonstrated in
human primary granulosa cells, where pCREB achieved
higher activation levels upon hCG treatment than LH, in
spite of lower ERK1/2 phosphorylation [19]. Therefore,
LHCGR activation results in qualitatively different, LH/
hCG specific pattern of simultaneously mediated signaling
cascades in human granulosa cells, different from that of
murine receptor in mouse Leydig cells. Results from the
gene expression analysis corroborate the pCreb activation
pattern, since no different increase of LH- and hCG-
induced Stard1 gene expression levels were observed.
Indeed, in murine Leydig cells, Stard1 gene expression
occurs as a pCreb-dependent event [13], although several
other modulators of the steroidogenic response were
described [43].
Both gonadotropins stimulate testosterone production
in a dose-dependent manner, but no significant differ-
ences between hCG- and LH- induced steroid synthesis
occur, as demonstrated by similar EC50s, corroborating
the upstream steroidogenic pCreb activation and Stard1
gene expression. PkA and Mek selective blockade by
H89 and U0126 inhibitors resulted in complete testos-
terone synthesis suppression, demonstrating that both
PkA and pErk1/2 are required for Leydig cells steroido-
genesis. The multiplicity of the signaling pathways
simultaneously mediated by GPCR [44] could be the
cause of progressively accumulated downstream modula-
tory events which mask the differences observed in the
early cell signaling.
Mouse Leydig and human granulosa cells: two different
endocrine systems
Our results indicate that different downstream LH- and
hCG-dependent signaling characterize primary mouse
Leydig and human granulosa cells [18], reflecting the
specific physiological role of these systems in relation to
LH-like hormone stimulations. However, qualitatively
different LH/hCG-dependent intracellular signals occur
between human granulosa [18] and mouse Leydig cells
in vitro, suggesting diverse receptor sequences and/or
intracellular milieu as origin of the difference.
In adult mice, Leydig cells regulate spermatogenesis
through testosterone production by pituitary LH stimu-
lation, which plays a key role in maintenance of fertility
in a follicle-stimulating hormone (FSH)-independent
manner [45–47]. Indeed, testosterone treatment recover
the number of mature spermatids and fertility in mLhr
knock-out mice [48, 49], as well as hCG injection in
gonadotropin-deficient hpg mice [50]. No wide differ-
ences exist between mouse and human spermatogenesis,
where testosterone is fundamental for the maturation of
gametes and maintenance of fertility exerting prolifera-
tive and anti-apoptotic roles [51, 52], indicating that, in
both the mammals, spermatogenesis is testosterone-
dependent. Indeed, spermatogenesis can be restored also
in gonadotropin-suppressed men inducing testosterone
production by hCG treatment [53].
In women of fertile age, LH regulates folliculogenesis
together with FSH and estrogens, and induces ovulation.
Pituitary gonadotropins stimulate the concerted action
of theca and granulosa cells to produce estrogens, result-
ing in dominant follicle growth while others undergo
atresia. The role exerted by LH during this period seems
to be unique and may not be easily replicated by hCG,
since it is not equivalent to LH at the molecular level
[18–20]. Even artificial cycles induced by clinical admin-
istration of gonadotropins for assisted reproduction fail
to reproduce exactly the natural cycle, inducing multi-
ovulations in a mono-ovulatory species. On the other
hand, hCG is produced exclusively during pregnancy,
except very low amount of pituitary hCG [5], when the
ovarian functions are mainly focused to the production
of relatively high progesterone levels instead of follicle
growth.
Taken together, these data suggest that mouse/rat in
vivo bioassays may not be fully informative of LH/hCG
bioactivity/action, given the functional diversity of the
rodent Leydig and human granulosa/theca cell systems.
Further studies may evaluate the LH/hCG-mediated
intracellular signals in human Leydig cells, which should
provide a better in vitro system to be compared to hu-
man primary granulosa cells. However, the poor avail-
ability of human Leydig cell donors will be a challenging
limitation in this regard.
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Different ligand-LH receptor features between human
and mouse
It was recently reported that murine receptor is able to
mediate qualitatively different response to LH and hCG,
both in terms of cAMP/PKA- and β-arrestin-dependent
pathways in transfected HEK293 cells, as well as down-
stream steroid synthesis in mLTC-1 cells endogenously
expressing mLhr [54]. These data suggest that trans-
fected/tumor cell lines may not be fully representative of
the wide range of gonadotropin-mediated intracellular
responses occurring in primary cells, as previously ob-
served [30, 55]. However, these findings confirm what was
previously observed in human granulosa cells [18, 19],
revealing that mouse primary Leydig cells provide some
limitations as a model for quantification of gonadotropins.
Murine Leydig cells are naturally expressing mLhr
sharing approximately 80% amino acid sequence identity
with LHCGR at the hinge region, which is responsible of
LH/hCG different cell signaling activation (Table 1). In
fact, there is a specific, distinct site of interaction located
within this region of the human receptor [15, 56, 57].
We could speculate that the mouse-specific amino acid
sequence at the hinge region is not able to qualitatively
discriminate between LH and hCG, reflecting the evolu-
tionary differences embedded into the primate-specific
LH and hCG dual ligand system. However, both human
gonadotropins retain binding capability to the murine
receptor [10]. Especially, the two human gonadotropins
have similar quantitative binding to, but different affin-
ities for mLhr [58]. This is due to low dissociation rate
of the bound hCG, which contributes to its higher bio-
activity than LH and may explain the quantitatively dif-
ferent cAMP recruitment elicited in vitro, demonstrated
by our experiments. However, in the mouse Leydig
tumor cells mLTC-1, both the human LH and hCG
exhibit different reversibility of cAMP activation than
rat and other mammals’ LHs [21], suggesting that rodent
Leydig cells do not provide a system properly exploitable
for human gonadotropin characterization, in spite of
receptor binding.
Knowledge by in vivo models
Previous studies demonstrated the PkA-dependence of
pErk1/2 activation in mouse primary Leydig cells and
tumor cell lines naturally expressing Lhr [59–62]. More-
over, the role of Erk1/2 in steroidogenesis and cell prolifer-
ation was extensively studied, both in vitro and in vivo,
revealing the importance of the Erk1/2 signaling for Ley-
dig cell functioning and steroidogenesis [22, 59, 63–66].
However, a clear comparison between LH and hCG in
Leydig cells was never performed. Interesting data were
provided by transgenic mouse models overexpressing
hCG, instead of physiological levels of murine LH. Exag-
gerated hCG-induced signaling was linked to infertility
and morphological alterations, including Leydig cell aden-
omas, in genetically modified mice [67–69]. Similar results
were obtained in LHCGR knock-in mice [70]. On the
other hands, transgenic mice overexpressing a chimeric
LH containing the C-terminal peptide of hCG, resulting in
extended hormone half-life with LH activity, leads to
infertility, polycystic ovaries, and ovarian tumors [71].
Taken together, these data reveal the wide spectrum of ef-
fects mediated by Lhr at the physiological level, however,
further efforts should be done to address the molecular
mechanisms by which human gonadotropins exert their
action through murine Lhr. These knowledge may be
plausibly provided by in vitro studies.
Conclusions
Our results demonstrated that human LH and hCG acti-
vate only quantitatively different, but qualitatively similar
early signaling and equal downstream steroid synthesis
in vitro in murine Leydig cells, raising concerns about
the appropriateness of rodent in vivo bioassays evaluating
LH/hCG-dependent endpoints. No different downstream
LH/hCG-specific steroidogenic events are in contrast to
what was observed in human primary granulosa cells, sug-
gesting some limitations of the male mouse as a model for
quantification of gonadotropins to be used for clinical pur-
poses in human female. The functional diversity between
human and rodent cell systems expressing orthologous re-
ceptors may affect the in vivo bioactivity of gonadotropins
and reflects the evolutionary differences on reproductive
endocrinology of these mammals. LH/hCG is a primate-
specific ligand system acting on structurally and function-
ally different cells and receptor.
Additional files
Additional file 1: Comparison between absolute levels of LH- and hCG-
induced cAMP production by dose–response experiment. Murine primary
Leydig cells were stimulated by increasing doses of hCG and LH, in the
presence of 500 μM IBMX. Total cAMP was measured after 3 h of incubation.
All the results are represented as means ± SEM in a logarithmic X-axis, then
non-linear regressions were plotted (n = 4). (TIF 592 kb)
Additional file 2: Comparison between LH- and hCG-induced production
of 17alpha-OH-progesterone measured by LC/MS. In order to confirm the
reliability of testosterone levels detected by immunoassay (Fig. 4), the
hormone was measured in 24 h-stimulated cells by EC80 LH and hCG, in the
presence of 500 μM IBMX. Total steroid levels were measured by LC/MS and
represented as means ± SEM (ng/ml; n = 2). (TIF 351 kb)
Additional file 3: Androstenedione levels measured by LC/MS, in LH- or
hCG-stimulated Leydig cells. Androstenedione was measured in 24 h-
stimulated cells by EC80 LH and hCG, in the presence of 500 μM IBMX.
Hormone levels were means ± SEM (ng/ml; n = 2). (TIF 372 kb)
Additional file 4: Comparison between LH- and hCG-induced testosterone
levels measured by LC/MS. Testosterone levels detected by immunoassay
(Fig. 4) were confirmed using the LC/MS method. Hormone levels were
measured in 24 h-stimulated cells by EC80 LH and hCG, in the presence of
500 μM IBMX. Total testosterone levels were represented as means ± SEM
(ng/ml; n= 2). (TIF 347 kb)
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Additional file 5: Alignment of LH receptor amino acid sequences
obtained from the UniProt database (http://www.uniprot.org). Homo
sapiens LHCGR (UniProt identifier: P22888), Mus musculus Lhr (P30730)
and Rattus norvegicus Lhr (P16235) sequences were aligned by the
UniProt online tool Clustal Omega 1.2.1 (http://www.uniprot.org/align).
Boxes indicate sequence divergence; :=conservation of strong groups;. =
conservation of weak groups or no consensus. (DOC 92 kb)
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